雄激素受体信号通路在去势抵抗性前列腺癌中作用机制的研究进展  

Research progress of androgen receptor signaling pathway in castration-resistant prostate cancer

作　　者：杨拓[1] 蔡科科[1] 卢炳新[1] Yang Tuo;Cai Keke;Lu Bingxin(Depaartment of Urology,Tianjin NanKai Hospital,NanKai university affiliated NanKai hospital,Tianjin Key Laboratory of Acute Abdominal Organ Injury and Repair of Traditional Chinese and Western Medicine,Tianjin 300102,China)

机构地区：[1]天津市南开医院泌尿外科,南开大学附属南开医院,天津市急腹症器官损伤与中西医修复重点实验室,天津300102

出　　处：《国际生物医学工程杂志》2022年第5期458-461,467,共5页International Journal of Biomedical Engineering

摘　　要：目前,前列腺癌是世界上最常见的男性恶性肿瘤,是世界男性癌症死亡人数仅次于肺癌的癌症,雄激素阻断疗法(ADT)是前列腺癌除根治性手术之外的一种主要治疗手段,但是经过ADT后,将会导致前列腺癌不可避免地进展为去势抵抗性前列腺癌(CRPC)。从激素依赖性前列腺癌(ADPC)到CRPC的转化过程,现阶段已经被证实与雄激素受体信号通路的重新激活有关。主要对雄激素受体信号通路在CRPC中作用机制的研究进展进行综述,为CRPC的诊断治疗提供科学依据和新的思路。Prostate cancer is the most common male malignant tumor in the world,and its death toll is second only to lung cancer.Androgen deprivation therapy(ADT)is a major treatment for prostate cancer besides radical surgery.ADT treatment will lead to the inevitable progression of prostate cancer patients to castration-resistant prostate cancer(CRPC).The current research results have confirmed that the transformation from androgen deprivation prostate cancer(ADPC)to CRP is related to the reactivation of the androgen receptor signal pathway.In this review,the research progress on the mechanism of the androgen receptor signaling pathway in CRPC was reviewed in order to provide a scientific basis and new ideas for the diagnosis and treatment of CRP.

关 键 词：雄激素受体 信号通路 去势抵抗性前列腺癌 作用机制 

分 类 号：R737.25[医药卫生—肿瘤]